The dearth of new antibiotic development: why we should be worried and what we can do about it

@article{Charles2004TheDO,
  title={The dearth of new antibiotic development: why we should be worried and what we can do about it},
  author={Patrick G. P. Charles and M. Lindsay Grayson},
  journal={Medical Journal of Australia},
  year={2004},
  volume={181}
}
The emergence and spread of multidrug‐resistant pathogens has increased substantially over the past 20 years. Over the same period, the development of new antibiotics has decreased alarmingly, with many pharmaceutical companies pulling out of antibiotic research in favour of developing “lifestyle” drugs. Reasons given for withdrawing from antibiotic development include poor “net present value” status of antibiotics, changes in regulations requiring larger drug trials and prolonged post… 

Dry antibiotic pipeline: Regulatory bottlenecks and regulatory reforms

Various regulatory bottlenecks in the development of novel antibacterial drugs are discussed, including draft guidance on scientific justification of margins in non‐inferiority trials for treatments of acute bacterial skin and skin structure infections.

[The role of the pharmaceutical industry. Why aren't new antibiotics being marketed?].

  • C. García-rey
  • Medicine
    Enfermedades infecciosas y microbiologia clinica
  • 2010

New Strategies for Antibacterial Drug Design

In the future, it is likely that most antibacterial drug design will be based on existing antibacterials, but an increasing number of new molecular antibacterial structures may emerge from screening against multiplying and perhaps non-multiplying bacteria.

Policies and Incentives for Promoting Innovation in Antibiotic Research

This book analyses many proposed policies and incentive mechanisms and sheds light on the key issues that will help policy-makers reach informed, concrete decisions on how to avert this potential public health crisis.

Non-microbial Natural Products That Inhibit Drug-Resistant Staphylococcus aureus

The potential use of non-microbial natural products in controlling Staphylococcus aureus’s growth is discussed, and the underlying challenges in developing the natural products into clinical applications are discussed.

A New Era of Antibiotics: The Clinical Potential of Antimicrobial Peptides

The therapeutic potential of peptide-based antimicrobials is detailed, as well as the challenges needed to overcome in order for clinical translation, and how this novel class of antimicrobial compound may address the need for effective antibiotics are explored.

In Tepid Defense of Population Health: Physicians and Antibiotic Resistance

  • R. S. Saver
  • Medicine, Political Science
    American Journal of Law & Medicine
  • 2008
Increased use of financial incentives to reward physicians for compliance with recommended guidelines on antibiotic prescribing can provide a much needed jump-start to physician interest in antibiotic conservation and likely best address physicians' legitimate clinical autonomy concerns.

Tuberculosis into the 2010s: is the glass half full?

  • A. RalphN. AnsteyP. Kelly
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2009
During the 16 years since the World Health Organization declared tuberculosis (TB) a global emergency, major new challenges have emerged-in particular the spread of extensively drug-resistant

Managing Infection: From Agar Plate to Genome Scan

This chapter will focus on the diagnosis and management of the infection per se, while acknowledging that this forms only one part of the treatment plan, and there are at least three good reasons why this is necessary.

The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy.

  • P. CharlesM. Whitby M. Grayson
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2008
The vast majority of patients with CAP can be treated successfully with narrow-spectrum beta-lactam treatment, such as penicillin combined with doxycycline or a macrolide, and greater use of such therapy could potentially reduce the emergence of antibiotic resistance among common bacterial pathogens.
...

References

SHOWING 1-10 OF 30 REFERENCES

Trends in antimicrobial drug development: implications for the future.

The need for new antimicrobial agents is greater than ever because of the emergence of multidrug resistance in common pathogens, the rapid emergence of new infections, and the potential for use of

Why is big Pharma getting out of antibacterial drug discovery?

  • S. Projan
  • Political Science
    Current opinion in microbiology
  • 2003

Control of nosocomial antimicrobial-resistant bacteria: a strategic priority for hospitals worldwide.

  • D. GoldmannW. Huskins
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1997
Strategic goals for the control of resistant organisms should be formulated on the basis of multidisciplinary input from hospital personnel, and the resultant data should be used to design, implement, and evaluate systematic measures to increase the appropriate use of antimicrobial agents and basic infection control practices.

βLactam Antibiotics and βLactamases: Two Sides of a Continuing Story

The period since the introduction of p-lactam antibiotics for therapeutic purposes has been characterized by a number of phases during which the incidence of resistant bacteria causing clinical infections has been high; more recently, it has been the resistant gram-negative bacteria, including anaerobes, that have given cause for concern.

Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.

  • C. CarpenterH. Chambers
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2004
The rapid bactericidal activity, low potential for resistance, and promising safety profile associated with this agent will make it a useful addition to the growing armamentarium of antibiotics active against gram-positive pathogens.

Beta-lactam antibiotics and beta-lactamases: two sides of a continuing story.

  • M. Richmond
  • Biology, Medicine
    Reviews of infectious diseases
  • 1979
The period since the introduction of beta-lactam antibiotics for therapeutic purposes has been characterized by a number of phases during which the incidence of resistant bacteria causing clinical infections has been high, and the best way to achieve efficacy against resistant bacteria seems to have been to design antibiotics that are insensitive to hydrolysis by beta- lactamases.

5: Hospital‐in‐the‐home treatment of infectious diseases

A growing range of infections can be safely and effectively treated with parenteral antimicrobial therapy at home, including cellulitis, pyelonephritis, pneumonia, endocarditis, osteomyelitis, septic

Methicillin-resistant Staphylococcal aureus evolution in Australia over 35 years.

A different variety of community-acquired MRSA has recently been noted in eastern Australia, which has a similar antibiogram to the western strains, but an entirely different epidemiology, resembling that currently being experienced in parts of New Zealand.

Microbial Threats to Health: Emergence, Detection, and Response

The sobering conclusion is made, ten years after the IOM report on Emerging infections that the global burden of infectious disease on the United States has actually increased.

WHO Global Strategy for Containment of Antimicrobial Resistance: Executive Summary

This strategy is the product of collaborative efforts across WHO, particularly in the clusters of Commu-nicable Diseases, Health Technology and Pharmaceuticals, and Family and Community Health, with significant input from the staff at WHO Regional Offices and from many partners working with WHO worldwide.